Oslo – 25.08.11 – Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug The study will determine: The target patient population for the study will be HIV-patients whose immune system have not fully recovered (defined by CD4+ (helper) T-cell count in the interval 250-400 cells …
New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS. New data presented by researchers at the XVIII International AIDS Conference on Thursday, July 22 showed significant momentum for the emerging field of therapeutic vaccines, anti-immune …
Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection Bionor Pharma announced today presentation of data from its international multicenter double-blinded placebo-controlled phase IIB study at the IAS conference in Rome. As previously communicated, a statistically significant difference in viral load set point was observed between the Vacc-4x …
